Assunta Ingannato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Assunta Ingannato has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Benedetta Nacmias
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
13 shared publications - Silvia Bagnoli
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139 Florence, Italy
13 shared publications - Sandro Sorbi
IRCCS Fondazione Don Carlo Gnocchi ONLUS, 50143 Florence, Italy
10 shared publications - Valentina Bessi
Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy
9 shared publications - Giulia Giacomucci
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139 Florence, Italy
8 shared publications - Salvatore Mazzeo
Neurology Unit, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy
8 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 705
Multimodal Detection of Cognitive Impairment in Non-Neurological Rehabilitation Settings: The COGinREHAB Study Protocol
Background/Objectives: Cognitive impairment is highly prevalent among hospitalised adults but often remains under-recognised, particularly in non-neurological rehabilitation settings where clinical attention is mainly focused on physical recovery. Undetected cognitive impairment may adversely affect rehabilitation outcomes, functional recovery, and long-term care planning. Methods: A multicentre, prospective, longitudinal study, with a single-group assignment and a diagnostic purpose, will be conducted across three rehabilitation centres of the Don Carlo Gnocchi Foundation (Italy), enrolling 384 patients aged ≥45 years without severe psychiatric or neurological disorders, other than cognitive impairment, admitted to cardiac, pulmonary, orthopaedic rehabilitation, or intermediate care units for non-neurological conditions. At baseline (T0), all participants will undergo standardised clinical and cognitive screening. Individuals with suspected cognitive impairment, operationally defined as an Equivalent Score (ES) of 1 on the Montreal Cognitive Assessment–MoCA total score and/or an ES of 0 or 1 on at least one MoCA cognitive domain, including the Memory Index Score (MIS), and a random sample of those without, will undergo a comprehensive neuropsychological assessment. Participants with neuropsychologically defined cognitive impairment, based on objective deficits in the comprehensive neuropsychological assessment, will undergo plasma biomarker testing (GFAP, NfL, pTau-217), APOE genotyping, and brain CT. Participants with a MoCA total ES of 0 will be classified as having cognitive impairment on the basis of screening alone. At two prespecified sites, consecutive consenting participants with neuropsychologically defined cognitive impairment will additionally undergo an EEG vigilance protocol, auditory P300 recording, seven-day actigraphy, and overnight polysomnography. Patients with neuropsychologically defined cognitive impairment at T0 will undergo a 12-month follow-up assessment (T1) of the progression of cognitive impairment and plasma biomarkers; those enrolled in the neurophysiological substudy will additionally repeat the EEG vigilance protocol. Expected Results: The study will provide a conservative (lower-bound) estimate of the prevalence of documented and non-documented cognitive impairment, together with an estimate corrected for partial verification bias, in non-neurological rehabilitation settings. It will further characterise the cognitive profiles and examine their correlations with biomarkers of neurodegeneration (GFAP, NfL, pTau-217), APOE genotype, relative EEG spectral power and sleep intrusion measures, P300 latency and amplitude, actigraphy-derived Sleep Efficiency, and polysomnography-derived sleep stage proportions. Longitudinal data will enable the evaluation of cognitive trajectories and their biological correlates. Conclusions: The COGinREHAB study addresses a critical gap in rehabilitation medicine by implementing a structured, multimodal approach to the identification and characterisation of cognitive impairment in patients with non-neurological conditions. Its findings may facilitate earlier detection of cognitive impairment and inform the development of personalised rehabilitation and care pathways. Trial registration: ClinicalTrials.gov, NCT07731334.
- 25 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 705
Open AccessMultimodal Detection of Cognitive Impairment in Non-Neurological Rehabilitation Settings: The COGinREHAB Study Protocol
Background/Objectives: Cognitive impairment is highly prevalent among hospitalised adults but often remains under-recognised, particularly in non-neurological rehabilitation settings where clinical attention is mainly focused on physical recovery. Undetected cognitive impairment may adversely affect rehabilitation outcomes, functional recovery, and long-term care planning. Methods: A multicentre, prospective, longitudinal study, with a single-group assignment and a diagnostic purpose, will be conducted across three rehabilitation centres of the Don Carlo Gnocchi Foundation (Italy), enrolling 384 patients aged ≥45 years without severe psychiatric or neurological disorders, other than cognitive impairment, admitted to cardiac, pulmonary, orthopaedic rehabilitation, or intermediate care units for non-neurological conditions. At baseline (T0), all participants will undergo standardised clinical and cognitive screening. Individuals with suspected cognitive impairment, operationally defined as an Equivalent Score (ES) of 1 on the Montreal Cognitive Assessment–MoCA total score and/or an ES of 0 or 1 on at least one MoCA cognitive domain, including the Memory Index Score (MIS), and a random sample of those without, will undergo a comprehensive neuropsychological assessment. Participants with neuropsychologically defined cognitive impairment, based on objective deficits in the comprehensive neuropsychological assessment, will undergo plasma biomarker testing (GFAP, NfL, pTau-217), APOE genotyping, and brain CT. Participants with a MoCA total ES of 0 will be classified as having cognitive impairment on the basis of screening alone. At two prespecified sites, consecutive consenting participants with neuropsychologically defined cognitive impairment will additionally undergo an EEG vigilance protocol, auditory P300 recording, seven-day actigraphy, and overnight polysomnography. Patients with neuropsychologically defined cognitive impairment at T0 will undergo a 12-month follow-up assessment (T1) of the progression of cognitive impairment and plasma biomarkers; those enrolled in the neurophysiological substudy will additionally repeat the EEG vigilance protocol. Expected Results: The study will provide a conservative (lower-bound) estimate of the prevalence of documented and non-documented cognitive impairment, together with an estimate corrected for partial verification bias, in non-neurological rehabilitation settings. It will further characterise the cognitive profiles and examine their correlations with biomarkers of neurodegeneration (GFAP, NfL, pTau-217), APOE genotype, relative EEG spectral power and sleep intrusion measures, P300 latency and amplitude, actigraphy-derived Sleep Efficiency, and polysomnography-derived sleep stage proportions. Longitudinal data will enable the evaluation of cognitive trajectories and their biological correlates. Conclusions: The COGinREHAB study addresses a critical gap in rehabilitation medicine by implementing a structured, multimodal approach to the identification and characterisation of cognitive impairment in patients with non-neurological conditions. Its findings may facilitate earlier detection of cognitive impairment and inform the development of personalised rehabilitation and care pathways. Trial registration: ClinicalTrials.gov, NCT07731334.
- Open Access
- 2 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4081
Cumulative Incidence in Monogenic Alzheimer’s Disease and Frontotemporal Dementia: Gene–Gene Interaction Effect
Monogenic forms of Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) represent the two principal neurodegenerative disorders leading to early-onset dementia, primarily linked to mutations in key AD- and FTD-associated genes. The marked heterogeneity in age at onset and penetrance among carriers of pathogenic mutations suggests that monogenic variants act within a broader polygenic background. The combined impact of AD- and FTD-related genetic variation on disease incidence in monogenic forms remains largely unexplored. Herein, we investigate gene–gene interaction patterns in monogenic AD and FTD, with a focus on genetic variability in key AD (APP, PSEN1, PSEN2) and FTD (MAPT, GRN, C9orf72)-associated genes and their association with cumulative disease incidence. Within the GARDENIA Consortium, we studied 426 individuals from Italian pedigrees, including patients (n = 319) and presymptomatic (n = 107) carriers of causative variants in APP (n = 39), PSEN1 (n = 71), PSEN2 (n = 13), MAPT (n = 29), GRN (n = 188), and C9orf72 (n = 86). Age at symptoms onset, age at last follow-up and sex were recorded. Whole exome sequencing was performed, focusing on non-causative variants (n = 64) in the key AD (APP, PSEN1, PSEN2) and FTD genes (MAPT, GRN, C9orf72). Weighted genetic burden scores were derived using Fine–Gray competing risk models to estimate variant-specific effects on cumulative AD and FTD incidence, accounting for mutually exclusive outcomes and family clustering. Model fit was evaluated using Akaike Information Criterion. Higher AD-risk-weighted burden scores in AD-related genes were associated with a significantly increased cumulative incidence of AD, while higher FTD-risk-weighted scores in FTD-related genes showed a trend toward association with increased cumulative incidence of FTD. A significant interaction between burden scores was observed. AD and FTD burden scores showed a negative interaction for AD (~79% attenuation) but a modest synergistic effect for FTD (~6% increase). These findings could imply context-dependent pleiotropy rather than simple additive genetic effects. Our study suggests that even in carriers oh highly penetrant AD or FTD causative variants, genetic background could substantially modulate cumulative disease incidence. Integrating polygenic information with monogenic status may improve prognostic stratification and inform precision approaches in dementia research and clinical trials.
- 2 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4081
Open AccessCumulative Incidence in Monogenic Alzheimer’s Disease and Frontotemporal Dementia: Gene–Gene Interaction Effect
Monogenic forms of Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) represent the two principal neurodegenerative disorders leading to early-onset dementia, primarily linked to mutations in key AD- and FTD-associated genes. The marked heterogeneity in age at onset and penetrance among carriers of pathogenic mutations suggests that monogenic variants act within a broader polygenic background. The combined impact of AD- and FTD-related genetic variation on disease incidence in monogenic forms remains largely unexplored. Herein, we investigate gene–gene interaction patterns in monogenic AD and FTD, with a focus on genetic variability in key AD (APP, PSEN1, PSEN2) and FTD (MAPT, GRN, C9orf72)-associated genes and their association with cumulative disease incidence. Within the GARDENIA Consortium, we studied 426 individuals from Italian pedigrees, including patients (n = 319) and presymptomatic (n = 107) carriers of causative variants in APP (n = 39), PSEN1 (n = 71), PSEN2 (n = 13), MAPT (n = 29), GRN (n = 188), and C9orf72 (n = 86). Age at symptoms onset, age at last follow-up and sex were recorded. Whole exome sequencing was performed, focusing on non-causative variants (n = 64) in the key AD (APP, PSEN1, PSEN2) and FTD genes (MAPT, GRN, C9orf72). Weighted genetic burden scores were derived using Fine–Gray competing risk models to estimate variant-specific effects on cumulative AD and FTD incidence, accounting for mutually exclusive outcomes and family clustering. Model fit was evaluated using Akaike Information Criterion. Higher AD-risk-weighted burden scores in AD-related genes were associated with a significantly increased cumulative incidence of AD, while higher FTD-risk-weighted scores in FTD-related genes showed a trend toward association with increased cumulative incidence of FTD. A significant interaction between burden scores was observed. AD and FTD burden scores showed a negative interaction for AD (~79% attenuation) but a modest synergistic effect for FTD (~6% increase). These findings could imply context-dependent pleiotropy rather than simple additive genetic effects. Our study suggests that even in carriers oh highly penetrant AD or FTD causative variants, genetic background could substantially modulate cumulative disease incidence. Integrating polygenic information with monogenic status may improve prognostic stratification and inform precision approaches in dementia research and clinical trials.
- 28 January 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (2) , 728-745
Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic
Background: Subjective cognitive decline (SCD) represents the first early symptomatic stage of Alzheimer's disease (AD). Objective: We aimed to investigate the relationships between features in SCD and to assess the importance of these features in the future development of dementia to inform a targeted management protocol. Methods: 440 SCD patients underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Relationships among features were first assessed univariately, focusing on differences across stratified subgroups. To capture multivariate associations, we applied network analysis using a Markov Random Field. Finally, baseline features were related to dementia progression using an XGboost machine learning model. Results: Women comprising 68.9% of the cohort, were generally younger at onset, had lower APOE ε4 prevalence, and differed in neuropsychological performance compared to men. Older patients (age >60) exhibited a higher prevalence of APOE ε4 and cerebral small vessel disease. Patients with depressive symptoms demonstrated lower cognitive performance across multiple domains. Network analysis indicated complex interconnections among gender, cognitive reserve, SCD severity, and depressive symptoms. The XGboost model achieved 74% accuracy in predicting progression to dementia, identifying age at onset, mini-mental state examination scores, and APOE genotype as the most predictive factors. Conclusions: This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. By identifying key predictive features, we propose a personalized management protocol aimed at optimizing care for individuals with SCD. Trial registration number: NCT05569083, registration date: 2019-05-30
- 28 January 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (2) , 728-745
Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic
Background: Subjective cognitive decline (SCD) represents the first early symptomatic stage of Alzheimer's disease (AD). Objective: We aimed to investigate the relationships between features in SCD and to assess the importance of these features in the future development of dementia to inform a targeted management protocol. Methods: 440 SCD patients underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Relationships among features were first assessed univariately, focusing on differences across stratified subgroups. To capture multivariate associations, we applied network analysis using a Markov Random Field. Finally, baseline features were related to dementia progression using an XGboost machine learning model. Results: Women comprising 68.9% of the cohort, were generally younger at onset, had lower APOE ε4 prevalence, and differed in neuropsychological performance compared to men. Older patients (age >60) exhibited a higher prevalence of APOE ε4 and cerebral small vessel disease. Patients with depressive symptoms demonstrated lower cognitive performance across multiple domains. Network analysis indicated complex interconnections among gender, cognitive reserve, SCD severity, and depressive symptoms. The XGboost model achieved 74% accuracy in predicting progression to dementia, identifying age at onset, mini-mental state examination scores, and APOE genotype as the most predictive factors. Conclusions: This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. By identifying key predictive features, we propose a personalized management protocol aimed at optimizing care for individuals with SCD. Trial registration number: NCT05569083, registration date: 2019-05-30
- 16 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (9) , 4349-4359
“Assessing relationship between blood MAPT methylation levels and clinical expression in Frontotemporal Dementia”
Introduction Little is known regarding the relationship between methylation levels and Frontotemporal Dementia (FTD). Objective The objective of the present study was to assess the relationship between blood MAPT methylation levels and clinical expression in FTD. Methods This cross-sectional observational study was conducted including 54 Italian patients with different phenotypes: 22 behavioral variant FTD (bvFTD), 10 semantic variant (svPPA), 22 non-fluent variant (nfv) Primary Progressive Aphasia (PPA). Results Results reveal a negative correlation between MAPT methylation levels determined by pyrosequencing analysis and the severity of disease in the FTD group and highlight an association between nfvPPA variant and intermediate-high levels of MAPT methylation, which persists also considering disease severity. Conclusions Our findings allow us to speculate that the degree of MAPT methylation in the blood, a test minimally invasive, cost-effective, and easily repeatable could be useful to differentiate FTD variants at onset and to confirm disease stage in symptomatic FTD patients. Further studies, also with a longitudinal design, are warranted to confirm our results.
- 16 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (9) , 4349-4359
“Assessing relationship between blood MAPT methylation levels and clinical expression in Frontotemporal Dementia”
Introduction Little is known regarding the relationship between methylation levels and Frontotemporal Dementia (FTD). Objective The objective of the present study was to assess the relationship between blood MAPT methylation levels and clinical expression in FTD. Methods This cross-sectional observational study was conducted including 54 Italian patients with different phenotypes: 22 behavioral variant FTD (bvFTD), 10 semantic variant (svPPA), 22 non-fluent variant (nfv) Primary Progressive Aphasia (PPA). Results Results reveal a negative correlation between MAPT methylation levels determined by pyrosequencing analysis and the severity of disease in the FTD group and highlight an association between nfvPPA variant and intermediate-high levels of MAPT methylation, which persists also considering disease severity. Conclusions Our findings allow us to speculate that the degree of MAPT methylation in the blood, a test minimally invasive, cost-effective, and easily repeatable could be useful to differentiate FTD variants at onset and to confirm disease stage in symptomatic FTD patients. Further studies, also with a longitudinal design, are warranted to confirm our results.
- Open Access
- 28 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4198
Evaluation of Illumina and Oxford Nanopore Sequencing for the Study of DNA Methylation in Alzheimer’s Disease and Frontotemporal Dementia
DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes. Alterations in DNA methylation patterns are associated with various brain disorders, including dementias such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Investigating these alterations is essential for understanding the pathogenesis and progression of these disorders. Among the various methods for detecting DNA methylation, DNA sequencing is one of the most widely employed. Specifically, two main sequencing approaches are commonly used for DNA methylation analysis: bisulfite sequencing and single-molecule long-read sequencing. In this review, we compared the performances of CpG methylation detection obtained using two popular sequencing platforms, Illumina for bisulfite sequencing and Oxford Nanopore (ON) for long-read sequencing. Our comparison considers several factors, including accuracy, efficiency, genomic regions, costs, wet-lab protocols, and bioinformatics pipelines. We provide insights into the strengths and limitations of both methods with a particular focus on their application in research on AD and FTD.
- 28 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4198
Open AccessEvaluation of Illumina and Oxford Nanopore Sequencing for the Study of DNA Methylation in Alzheimer’s Disease and Frontotemporal Dementia
DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes. Alterations in DNA methylation patterns are associated with various brain disorders, including dementias such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Investigating these alterations is essential for understanding the pathogenesis and progression of these disorders. Among the various methods for detecting DNA methylation, DNA sequencing is one of the most widely employed. Specifically, two main sequencing approaches are commonly used for DNA methylation analysis: bisulfite sequencing and single-molecule long-read sequencing. In this review, we compared the performances of CpG methylation detection obtained using two popular sequencing platforms, Illumina for bisulfite sequencing and Oxford Nanopore (ON) for long-read sequencing. Our comparison considers several factors, including accuracy, efficiency, genomic regions, costs, wet-lab protocols, and bioinformatics pipelines. We provide insights into the strengths and limitations of both methods with a particular focus on their application in research on AD and FTD.
- Open Access
- 27 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7035
Mutational Landscape of Alzheimer’s Disease and Frontotemporal Dementia: Regional Variances in Northern, Central, and Southern Italy
Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) are the two major neurodegenerative diseases with distinct clinical and neuropathological profiles. The aim of this report is to conduct a population-based investigation in well-characterized APP, PSEN1, PSEN2, MAPT, GRN, and C9orf72 mutation carriers/pedigrees from the north, the center, and the south of Italy. We retrospectively analyzed the data of 467 Italian individuals. We identified 21 different GRN mutations, 20 PSEN1, 11 MAPT, 9 PSEN2, and 4 APP. Moreover, we observed geographical variability in mutation frequencies by looking at each cohort of participants, and we observed a significant difference in age at onset among the genetic groups. Our study provides evidence that age at onset is influenced by the genetic group. Further work in identifying both genetic and environmental factors that modify the phenotypes in all groups is needed. Our study reveals Italian regional differences among the most relevant AD/FTD causative genes and emphasizes how the collaborative studies in rare diseases can provide new insights to expand knowledge on genetic/epigenetic modulators of age at onset.
- 27 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7035
Open AccessMutational Landscape of Alzheimer’s Disease and Frontotemporal Dementia: Regional Variances in Northern, Central, and Southern Italy
Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) are the two major neurodegenerative diseases with distinct clinical and neuropathological profiles. The aim of this report is to conduct a population-based investigation in well-characterized APP, PSEN1, PSEN2, MAPT, GRN, and C9orf72 mutation carriers/pedigrees from the north, the center, and the south of Italy. We retrospectively analyzed the data of 467 Italian individuals. We identified 21 different GRN mutations, 20 PSEN1, 11 MAPT, 9 PSEN2, and 4 APP. Moreover, we observed geographical variability in mutation frequencies by looking at each cohort of participants, and we observed a significant difference in age at onset among the genetic groups. Our study provides evidence that age at onset is influenced by the genetic group. Further work in identifying both genetic and environmental factors that modify the phenotypes in all groups is needed. Our study reveals Italian regional differences among the most relevant AD/FTD causative genes and emphasizes how the collaborative studies in rare diseases can provide new insights to expand knowledge on genetic/epigenetic modulators of age at onset.
- Open Access
The Huntington’s Disease Gene in an Italian Cohort of Patients with Bipolar Disorder
Background and objectives: Huntington’s disease (HD) is characterized by motor, cognitive and psychiatric manifestations and caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27–35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and evaluate any differences between bipolar patients carrying the normal HTT allele and patients with the expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients who were affected by either type 1 or type 2 bipolar disorder. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at the onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls. The identification of this subset of bipolar subjects has implications for the clinical management of patients and their family members and promotes further investigation into possible pathological mechanisms common to both HD and bipolar disorder.
Open AccessThe Huntington’s Disease Gene in an Italian Cohort of Patients with Bipolar Disorder
Background and objectives: Huntington’s disease (HD) is characterized by motor, cognitive and psychiatric manifestations and caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27–35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and evaluate any differences between bipolar patients carrying the normal HTT allele and patients with the expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients who were affected by either type 1 or type 2 bipolar disorder. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at the onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls. The identification of this subset of bipolar subjects has implications for the clinical management of patients and their family members and promotes further investigation into possible pathological mechanisms common to both HD and bipolar disorder.
- Open Access
- 9 August 2023
- Published by MDPI AG in Preprints.org
The Huntington’s Disease Gene in an Italian Cohort of Patients With Bipolar Disorder
Background and objectives: Huntington disease (HD) is characterized by motor, cognitive and psychiatric manifestations and is caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27-35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and to evaluate any differences between bipolar patients carrying normal HTT allele and patients with expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients affected by bipolar disorder type 1 and type 2. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls.
- 9 August 2023
- Published by MDPI AG in Preprints.org
Open AccessThe Huntington’s Disease Gene in an Italian Cohort of Patients With Bipolar Disorder
Background and objectives: Huntington disease (HD) is characterized by motor, cognitive and psychiatric manifestations and is caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27-35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and to evaluate any differences between bipolar patients carrying normal HTT allele and patients with expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients affected by bipolar disorder type 1 and type 2. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls.
- Open Access
- 5 July 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 232, 107875
Sex influences clinical phenotype in valosin-containing protein mutations: A case family report and systematic literature review
- 5 July 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 232, 107875
Open AccessSex influences clinical phenotype in valosin-containing protein mutations: A case family report and systematic literature review